TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citi Removes Two names from 90-Day Catalyst Watch Lists
October 31, 2024 4:06 PM EDTCiti Removes Two names from 90-Day Catalyst Watch Lists
Tandem Diabetes (NASDAQ: TNDM) Removed from 90-Day Downside Catalyst Watch List: "With our 3Q24 Preview (10/1/24), we opened a 90-day Negative Catalyst Watch on TNDM. The thesis was: 1) survey results suggested ~flat Tandem share of new patient starts in the U.S. in the 3Q24E; 2) while Mobi prescriptions were increasing, it... MoreGoldman Sachs Reiterates Buy Rating on Edwards Lifesciences (EW)
October 30, 2024 4:16 PM EDTGoldman Sachs analyst David Roman reiterated a Buy rating and $80.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "Overall, we think confirmatory results for the full cohort of TRISCEND II was broadly expected by investors we have spoken... More
BofA Securities Reiterates Neutral Rating on Edwards Lifesciences (EW)
October 30, 2024 4:03 PM EDTBofA Securities analyst Travis Steed reiterated a Neutral rating and $75.00 price target on Edwards Lifesciences (NYSE: EW).
The analyst comments "On Wednesday EW hosted a TMTT investor event after Evoque pivotal data were presented. See TRISCEND II at TCT report for our initial take on the data. We go over the key... More
